Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress Pharmaceutical Investing
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis Pharmaceutical Investing
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea Pharmaceutical Investing
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing Pharmaceutical Investing
BOTOX® Cosmetic Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories Pharmaceutical Investing
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 Pharmaceutical Investing
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness Pharmaceutical Investing
I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments Pharmaceutical Investing
